Advertisement
Singapore markets closed

  • Straits Times Index

    3,306.02
    +6.02 (+0.18%)
     

  • Nikkei

    38,596.47
    -36.55 (-0.09%)
     

  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • Bitcoin USD

    64,131.42
    -850.77 (-1.31%)
     

  • CMC Crypto 200

    1,329.07
    -31.25 (-2.30%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • Dow

    39,150.33
    +15.57 (+0.04%)
     

  • Nasdaq

    17,689.36
    -32.23 (-0.18%)
     

  • Gold

    2,334.90
    -34.10 (-1.44%)
     

  • Crude Oil

    80.64
    -0.65 (-0.80%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • FTSE Bursa Malaysia

    1,590.37
    -2.32 (-0.15%)
     

  • Jakarta Composite Index

    6,879.98
    +60.66 (+0.89%)
     

  • PSE Index

    6,158.48
    -186.08 (-2.93%)
     

Nektar Management to Present at Upcoming Investor Conferences

PR Newswire
·2-min read

SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:

(PRNewsfoto/Nektar Therapeutics)
(PRNewsfoto/Nektar Therapeutics)

  • Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time

  • Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time

The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until July 6, 2024 and July 10, 2024, respectively.

ADVERTISEMENT

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302160077.html

SOURCE Nektar Therapeutics